Michael B. Lilly

TitleEndowed Chair, Oliver S. and Jennie R. Donaldson Charitable Trust Endowed Chair
InstitutionMedical University of South Carolina
DepartmentHematology/Oncology
AddressP.O. Box MSC 635
355A
86 Jonathan Lucas St.
Phone843-792-4271
vCardDownload vCard

    Collapse Overview 
    Collapse keywords
    Cancer, Cancer/Breast, Cancer/Gastrointestinal, Cancer/Genitourinary, Cancer/Lung, Men-s Health, Cancer/Lymphoma, Cancer/Other, Drug Studies, Prostate, Healthy Volunteer Studies

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Janneh AH, Kassir MF, Atilgan FC, Lee HG, Sheridan M, Oleinik N, Szulc Z, Voelkel-Johnson C, Nguyen H, Li H, Peterson YK, Marangoni E, Saatci O, Sahin O, Lilly M, Atkinson C, Tomlinson S, Mehrotra S, Ogretmen B. Crosstalk between pro-survival sphingolipid metabolism and complement signaling induces inflammasome-mediated tumor metastasis. Cell Rep. 2022 12 06; 41(10):111742. PMID: 36476873; PMCID: PMC9791981.
      Citations:    Fields:    Translation:HumansAnimals
    2. Babatunde OA, Pearce JL, Jefferson MS, Frey LJ, Angel PM, Drake RR, Allen CG, Lilly MB, Savage SJ, Hughes Halbert C. Racial Distribution of Neighborhood-Level Social Deprivation in a Retrospective Cohort of Prostate Cancer Survivors. Diseases. 2022 Oct 03; 10(4). PMID: 36278574; PMCID: PMC9589959.
      Citations: 1     
    3. Zimmerman R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Hernanadez EJ, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N, Barata PC. Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. Oncologist. 2022 Oct 01; 27(10):e815-e818. PMID: 36036607; PMCID: PMC9526493.
      Citations:    Fields:    Translation:Humans
    4. Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N. Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. Front Oncol. 2022; 12:966534. PMID: 36185208; PMCID: PMC9521349.
      Citations:    
    5. Orr RK, Hoehn JL, Col NF, Bray AW, Duan R, Malalur P, Drusbosky LM, Gourdin TS, Hill EG, Lilly MB. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer. Prostate. 2022 09; 82(13):1264-1272. PMID: 35766303; PMCID: PMC9388585.
      Citations: 1     Fields:    Translation:Humans
    6. Wang X, Zhou Z, Turner D, Lilly M, Ou T, Jiang W, Wang X, Zhou Z, Turner D, Lilly M, Ou T, Jiang W. Differential Circulating Fungal Microbiome in Prostate Cancer Patients Compared to Healthy Control Individuals. J Immunol Res. 2022; 2022:2574964. PMID: 35155686; PMCID: PMC8831061.
      Citations:    
    7. Krisanits BA, Woods P, Nogueira LM, Woolfork DD, Lloyd CE, Baldwin A, Frye CC, Peterson KD, Cosh SD, Guo QJ, Spruill LS, Lilly MB, Helke K, Li H, Hanna GS, Hamann MT, Thomas C, Ahmed M, Gooz MB, Findlay VJ, Turner DP, Krisanits BA, Woods P, Nogueira LM, Woolfork DD, Lloyd CE, Baldwin A, Frye CC, Peterson KD, Cosh SD, Guo QJ, Spruill LS, Lilly MB, Helke K, Li H, Hanna GS, Hamann MT, Thomas C, Ahmed M, Gooz MB, Findlay VJ, Turner DP. Non-enzymatic glycoxidation linked with nutrition enhances the tumorigenic capacity of prostate cancer epithelia through AGE mediated activation of RAGE in cancer associated fibroblasts. Transl Oncol. 2022 Jan 25; 17:101350. PMID: 35091340; PMCID: PMC8802052.
      Citations:    
    8. Zhuang E, Uchio E, Lilly M, Zi X, Fruehauf JP, Zhuang E, Uchio E, Lilly M, Zi X, Fruehauf JP. A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer. Biomed Pharmacother. 2021 Nov; 143:112226. PMID: 34649352; PMCID: PMC9886492.
      Citations:    
    9. Knochelmann HM, Rivera-Reyes AM, Wyatt MM, Smith AS, Chamness R, Dwyer CJ, Bobian M, Rangel Rivera GO, Horton JD, Lilly M, Romeo MJ, Timmers CD, Rubinstein MP, Neskey DM, Paulos CM, Knochelmann HM, Rivera-Reyes AM, Wyatt MM, Smith AS, Chamness R, Dwyer CJ, Bobian M, Rangel Rivera GO, Horton JD, Lilly M, Romeo MJ, Timmers CD, Rubinstein MP, Neskey DM, Paulos CM. Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies. Oncoimmunology. 2021; 10(1):1959101. PMID: 34408920; PMCID: PMC8366547.
      Citations:    
    10. Rahmatpanah F, Robles G, Lilly M, Keane T, Kumar V, Mercola D, Randhawa P, McClelland M, Rahmatpanah F, Robles G, Lilly M, Keane T, Kumar V, Mercola D, Randhawa P, McClelland M. RNA expression differences in prostate tumors and tumor-adjacent stroma between Black and White Americans. Oncotarget. 2021 Jul 20; 12(15):1457-1469. PMID: 34316327; PMCID: PMC8310667.
      Citations:    
    11. Halbert CH, Jefferson M, Allen CG, Babatunde OA, Drake R, Angel P, Savage SJ, Frey L, Lilly M, Obi T, Obeid J, Halbert CH, Jefferson M, Allen CG, Babatunde OA, Drake R, Angel P, Savage SJ, Frey L, Lilly M, Obi T, Obeid J. Racial Differences in Patient Portal Activation and Research Enrollment Among Patients With Prostate Cancer. JCO Clin Cancer Inform. 2021 06; 5:768-774. PMID: 34328797; PMCID: PMC8812608.
      Citations:    
    12. Bauer AG, Jefferson M, Nahhas GJ, Savage S, Drake R, Lilly M, Ambrose L, Caulder S, Mahvi D, Hughes Halbert C, Bauer AG, Jefferson M, Nahhas GJ, Savage S, Drake R, Lilly M, Ambrose L, Caulder S, Mahvi D, Hughes Halbert C. Financial toxicity and strain among men receiving prostate cancer care in an equal access healthcare system. Cancer Med. 2020 12; 9(23):8765-8771. PMID: 33070458; PMCID: PMC7724486.
      Citations:    
    13. Moses M, Niu A, Lilly MB, Hahn AW, Nussenzveig R, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J, Agarwal N, Sartor O, Barata PC, Moses M, Niu A, Lilly MB, Hahn AW, Nussenzveig R, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J, Agarwal N, Sartor O, Barata PC. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100193. PMID: 32702615.
      Citations:    
    14. Halbert CH, Jefferson MS, Drake R, Lilly M, Savage SJ, Nahhas GJ, Price ST, Loftley AE, Bauer A, Halbert CH, Jefferson MS, Drake R, Lilly M, Savage SJ, Nahhas GJ, Price ST, Loftley AE, Bauer A. Social and clinical determinants of physical activity in prostate cancer survivors. Support Care Cancer. 2021 Jan; 29(1):459-465. PMID: 32394247; PMCID: PMC7655513.
      Citations:    
    15. Jefferson M, Drake RR, Lilly M, Savage SJ, Tucker Price S, Hughes Halbert C, Jefferson M, Drake RR, Lilly M, Savage SJ, Tucker Price S, Hughes Halbert C. Co-morbidities in a Retrospective Cohort of Prostate Cancer Patients. Ethn Dis. 2020; 30(Suppl 1):185-192. PMID: 32269460; PMCID: PMC7138439.
      Citations:    
    16. Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M, Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 06 01; 26(11):2546-2555. PMID: 32034076.
      Citations:    
    17. Ou T, Zhou Z, Turner DP, Zhu B, Lilly M, Jiang W, Ou T, Zhou Z, Turner DP, Zhu B, Lilly M, Jiang W. Increased Preoperative Plasma Level of Microbial 16S rDNA Translocation Is Associated With Relapse After Prostatectomy in Prostate Cancer Patients. Front Oncol. 2019; 9:1532. PMID: 32010622; PMCID: PMC6974797.
      Citations:    
    18. Orr RK, Hoehn JL, Col NF, Metelli A, Wu BX, Riesenberg B, Guglietta S, Huck JD, Mills C, Li A, Rachidi S, Krieg C, Rubinstein MP, Gewirth DT, Sun S, Lilly MB, Wahlquist AH, Carbone DP, Yang Y, Liu B, Li Z. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-?. Sci Transl Med. 2020 01 08; 12(525). PMID: 31915300; PMCID: PMC7814995.
      Citations:    
    19. Ledet EM, Lilly MB, Sonpavde G, Lin E, Nussenzveig RH, Barata PC, Yandell M, Nagy RJ, Kiedrowski L, Agarwal N, Sartor O, Ledet EM, Lilly MB, Sonpavde G, Lin E, Nussenzveig RH, Barata PC, Yandell M, Nagy RJ, Kiedrowski L, Agarwal N, Sartor O. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. Oncologist. 2020 04; 25(4):327-333. PMID: 32297439; PMCID: PMC7160408.
      Citations:    
    20. Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB, Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. 2019 05 01; 125(9):1459-1469. PMID: 30620391.
      Citations:    
    21. Walter KR, Ford ME, Gregoski MJ, Kramer RM, Knight KD, Spruill L, Nogueira LM, Krisanits BA, Phan V, La Rue AC, Lilly MB, Ambs S, Chan K, Turner TF, Varner H, Singh S, Uribarri J, Garrett-Mayer E, Armeson KE, Hilton EJ, Clair MJ, Taylor MH, Abbott AM, Findlay VJ, Peterson LL, Magwood G, Turner DP, Walter KR, Ford ME, Gregoski MJ, Kramer RM, Knight KD, Spruill L, Nogueira LM, Krisanits BA, Phan V, La Rue AC, Lilly MB, Ambs S, Chan K, Turner TF, Varner H, Singh S, Uribarri J, Garrett-Mayer E, Armeson KE, Hilton EJ, Clair MJ, Taylor MH, Abbott AM, Findlay VJ, Peterson LL, Magwood G, Turner DP. Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. Breast Cancer Res Treat. 2019 Feb; 173(3):559-571. PMID: 30368741; PMCID: PMC6394600.
      Citations:    
    22. Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN, Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol. 2018 Oct 19; JCO1800328. PMID: 30339520; PMCID: PMC6286162.
      Citations:    
    23. Ou T, Lilly M, Jiang W, Ou T, Lilly M, Jiang W. The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer. Front Immunol. 2018; 9:1188. PMID: 29928275; PMCID: PMC5998742.
      Citations:    
    24. Orr RK, Hoehn JL, Col NF, Goicochea NL, Garnovskaya M, Blanton MG, Chan G, Weisbart R, Lilly MB. Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy. Protein Eng Des Sel. 2017 12 01; 30(12):785-793. PMID: 29228299.
      Citations:    
    25. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA, Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest. 2017 06 01; 127(6):2438. PMID: 28569734; PMCID: PMC5451225.
      Citations:    
    26. Rice LJ, Jefferson M, Briggs V, Delmoor E, Johnson JC, Gattoni-Celli S, Savage SJ, Lilly M, Prasad SM, Kittles R, Halbert CH, Rice LJ, Jefferson M, Briggs V, Delmoor E, Johnson JC, Gattoni-Celli S, Savage SJ, Lilly M, Prasad SM, Kittles R, Halbert CH. Discordance in perceived risk and epidemiological outcomes of prostate cancer among African American men. Prev Med Rep. 2017 Sep; 7:1-6. PMID: 28507891; PMCID: PMC5423348.
      Citations:    
    27. Liu G, Zhang J, Frey L, Gang X, Wu K, Liu Q, Lilly M, Wu J, Liu G, Zhang J, Frey L, Gang X, Wu K, Liu Q, Lilly M, Wu J. Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue. J Hematol Oncol. 2017 01 11; 10(1):14. PMID: 28077171; PMCID: PMC5225646.
      Citations:    
    28. Habiel DM, Krepostman N, Lilly M, Cavassani K, Coelho AL, Shibata T, Elenitoba-Johnson K, Hogaboam CM, Habiel DM, Krepostman N, Lilly M, Cavassani K, Coelho AL, Shibata T, Elenitoba-Johnson K, Hogaboam CM. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma. Oncotarget. 2016 Dec 13; 7(50):83514-83529. PMID: 27835864; PMCID: PMC5347785.
      Citations:    
    29. Li X, Yokoyama NN, Zhang S, Ding L, Liu HM, Lilly MB, Mercola D, Zi X, Li X, Yokoyama NN, Zhang S, Ding L, Liu HM, Lilly MB, Mercola D, Zi X. Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. Oncotarget. 2015 Dec 08; 6(39):41809-24. PMID: 26497688; PMCID: PMC4747190.
      Citations:    
    30. Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C, Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther. 2015 Dec; 14(12):2744-52. PMID: 26494858; PMCID: PMC4674301.
      Citations:    
    31. Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM, Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10; 33(14):1601-8. PMID: 25847934; PMCID: PMC4417730.
      Citations:    
    32. Wang L, Li W, Lin M, Garcia M, Mulholland D, Lilly M, Martins-Green M, Wang L, Li W, Lin M, Garcia M, Mulholland D, Lilly M, Martins-Green M. Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis. 2014 Oct; 35(10):2321-30. PMID: 25023990; PMCID: PMC6276919.
      Citations:    
    33. Jia Z, Lilly MB, Koziol JA, Chen X, Xia XQ, Wang Y, Skarecky D, Sutton M, Sawyers A, Ruckle H, Carpenter PM, Wang-Rodriguez J, Jiang J, Deng M, Pan C, Zhu JG, McLaren CE, Gurley MJ, Lee C, McClelland M, Ahlering T, Kattan MW, Mercola D, Jia Z, Lilly MB, Koziol JA, Chen X, Xia XQ, Wang Y, Skarecky D, Sutton M, Sawyers A, Ruckle H, Carpenter PM, Wang-Rodriguez J, Jiang J, Deng M, Pan C, Zhu JG, McLaren CE, Gurley MJ, Lee C, McClelland M, Ahlering T, Kattan MW, Mercola D. Generation of "virtual" control groups for single arm prostate cancer adjuvant trials. PLoS One. 2014; 9(1):e85010. PMID: 24465467; PMCID: PMC3897405.
      Citations:    
    34. Mohan S, Huff E, Wish J, Lilly M, Chen SC, McClellan WM, Mohan S, Huff E, Wish J, Lilly M, Chen SC, McClellan WM, Fistula First Breakthrough Initiative Data Committee. Recovery of renal function among ESRD patients in the US medicare program. PLoS One. 2013; 8(12):e83447. PMID: 24358285; PMCID: PMC3866227.
      Citations:    
    35. Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB, Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53. PMID: 23652277; PMCID: PMC4165488.
      Citations:    
    36. Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR, Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012; 7(10):e46737. PMID: 23091600; PMCID: PMC3473028.
      Citations:    
    37. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA, Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013 Mar; 27(3):586-94. PMID: 23090679; PMCID: PMC3593948.
      Citations:    
    38. Robinson CA, Bottorff JL, Lilly MB, Reid C, Abel S, Lo M, Cummings GG, Robinson CA, Bottorff JL, Lilly MB, Reid C, Abel S, Lo M, Cummings GG. Stakeholder perspectives on transitions of nursing home residents to hospital emergency departments and back in two Canadian provinces. J Aging Stud. 2012 Dec; 26(4):419-27. PMID: 22939538.
      Citations:    
    39. Li X, Liu Z, Xu X, Blair CA, Sun Z, Xie J, Lilly MB, Zi X, Li X, Liu Z, Xu X, Blair CA, Sun Z, Xie J, Lilly MB, Zi X. Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice. PLoS One. 2012; 7(2):e31213. PMID: 22347450; PMCID: PMC3276576.
      Citations:    
    40. Romero Rosales K, Singh G, Wu K, Chen J, Janes MR, Lilly MB, Peralta ER, Siskind LJ, Bennett MJ, Fruman DA, Edinger AL, Romero Rosales K, Singh G, Wu K, Chen J, Janes MR, Lilly MB, Peralta ER, Siskind LJ, Bennett MJ, Fruman DA, Edinger AL. Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins. Biochem J. 2011 Oct 15; 439(2):299-311. PMID: 21767261; PMCID: PMC3454501.
      Citations:    
    41. Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M, Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24. PMID: 21532336.
      Citations:    
    42. Shieh MP, Mitsuhashi M, Lilly M, Shieh MP, Mitsuhashi M, Lilly M. Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. Clin Med Insights Oncol. 2011; 5:185-99. PMID: 21792346; PMCID: PMC3140277.
      Citations:    
    43. Tang Y, Parmakhtiar B, Simoneau AR, Xie J, Fruehauf J, Lilly M, Zi X, Tang Y, Parmakhtiar B, Simoneau AR, Xie J, Fruehauf J, Lilly M, Zi X. Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia. 2011 Feb; 13(2):108-19. PMID: 21403837; PMCID: PMC3033590.
      Citations:    
    44. Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, Lilly MB, De León M, Casiano CA, Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, Lilly MB, De Le?n M, Casiano CA. Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate. 2011 May 15; 71(7):755-65. PMID: 21031435; PMCID: PMC3107902.
      Citations:    
    45. Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, Cramer SD, Lilly MB, Kraft AS, Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, Cramer SD, Lilly MB, Kraft AS. Regulation of Skp2 levels by the Pim-1 protein kinase. J Biol Chem. 2010 Sep 17; 285(38):29128-37. PMID: 20663873; PMCID: PMC2937943.
      Citations:    
    46. Orr RK, Hoehn JL, Col NF, Zemskova M, Lilly MB, Lin YW, Song JH, Kraft AS. p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol Cancer Res. 2010 Aug; 8(8):1126-41. PMID: 20647331; PMCID: PMC3407470.
      Citations:    
    47. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G, Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, M?ller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70. PMID: 20131302.
      Citations:    
    48. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA, Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010 Feb; 16(2):205-13. PMID: 20072130; PMCID: PMC4017764.
      Citations:    
    49. Nga ME, Swe NN, Chen KT, Shen L, Lilly MB, Chan SP, Salto-Tellez M, Das K, Nga ME, Swe NN, Chen KT, Shen L, Lilly MB, Chan SP, Salto-Tellez M, Das K. PIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications. Int J Exp Pathol. 2010 Feb; 91(1):34-43. PMID: 19878356; PMCID: PMC2812726.
      Citations:    
    50. Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall NR, Lilly MB, De Leon M, Casiano CA, Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall NR, Lilly MB, De Leon M, Casiano CA. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer. 2009 Aug 28; 8:68. PMID: 19715609; PMCID: PMC2741463.
      Citations:    
    51. Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z, Lilly M, Smith CD, Kraft AS, Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z, Lilly M, Smith CD, Kraft AS. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther. 2009 Jun; 8(6):1473-83. PMID: 19509254; PMCID: PMC3415237.
      Citations:    
    52. Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS, Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther. 2009 May; 8(9):846-53. PMID: 19276681.
      Citations:    
    53. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA, Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest. 2008 Sep; 118(9):3038-50. PMID: 18704194; PMCID: PMC2515380.
      Citations:    
    54. Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB, Salto-Tellez M, Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB, Salto-Tellez M. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer. 2008 Oct; 44(15):2144-51. PMID: 18715779.
      Citations:    
    55. Zemskova M, Sahakian E, Bashkirova S, Lilly M, Zemskova M, Sahakian E, Bashkirova S, Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem. 2008 Jul 25; 283(30):20635-44. PMID: 18426800; PMCID: PMC3258959.
      Citations:    
    56. Zhou J, Pan M, Xie Z, Loh SL, Bi C, Tai YC, Lilly M, Lim YP, Han JH, Glaser KB, Albert DH, Davidsen SK, Chen CS, Zhou J, Pan M, Xie Z, Loh SL, Bi C, Tai YC, Lilly M, Lim YP, Han JH, Glaser KB, Albert DH, Davidsen SK, Chen CS. Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia. 2008 Jan; 22(1):138-46. PMID: 17943175.
      Citations:    
    57. Holder S, Lilly M, Brown ML, Holder S, Lilly M, Brown ML. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg Med Chem. 2007 Oct 01; 15(19):6463-73. PMID: 17637507.
      Citations:    
    58. Hansen JE, Fischer LK, Chan G, Chang SS, Baldwin SW, Aragon RJ, Carter JJ, Lilly M, Nishimura RN, Weisbart RH, Reeves ME, Hansen JE, Fischer LK, Chan G, Chang SS, Baldwin SW, Aragon RJ, Carter JJ, Lilly M, Nishimura RN, Weisbart RH, Reeves ME. Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer Res. 2007 Feb 15; 67(4):1769-74. PMID: 17308119.
      Citations:    
    59. Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS, Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS. Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A. Oncogene. 2007 Aug 02; 26(35):5145-53. PMID: 17297438.
      Citations:    
    60. Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB, Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 2007 Jan; 6(1):163-72. PMID: 17218638.
      Citations:    
    61. Zemskova M, Wechter W, Bashkirova S, Chen CS, Reiter R, Lilly MB, Zemskova M, Wechter W, Bashkirova S, Chen CS, Reiter R, Lilly MB. Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. Biochem Pharmacol. 2006 Nov 15; 72(10):1257-67. PMID: 16949054.
      Citations:    
    62. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS, Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 2005 Aug; 3(8):443-51. PMID: 16123140.
      Citations:    
    63. Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M, Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol. 2005 Feb; 173(2):604-9. PMID: 15643273.
      Citations:    
    64. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, Small D, Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, Small D. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood. 2005 Feb 15; 105(4):1759-67. PMID: 15498859.
      Citations:    
    65. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ, Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004 Jul 30; 571(1-3):43-9. PMID: 15280015.
      Citations:    
    66. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M, Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003 Nov 14; 278(46):45358-67. PMID: 12954615.
      Citations: 107     Fields:    Translation:HumansAnimalsCells
    67. Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly MB, Kraft AS, Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly MB, Kraft AS. Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res. 2003 Jan-Feb; 23(1A):167-78. PMID: 12680209.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    68. Frankel AE, Powell BL, Lilly MB, Frankel AE, Powell BL, Lilly MB. Diphtheria toxin conjugate therapy of cancer. Cancer Chemother Biol Response Modif. 2002; 20:301-13. PMID: 12703211.
      Citations: 4     Fields:    Translation:HumansAnimals
    69. Lilly MB, Zemskova M, Frankel AE, Salo J, Kraft AS, Lilly MB, Zemskova M, Frankel AE, Salo J, Kraft AS. Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit mediate activation of Jak/Stat signaling and differentiation. Blood. 2001 Mar 15; 97(6):1662-70. PMID: 11238105.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    70. Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, Kraft A, Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene. 1999 Jul 08; 18(27):4022-31. PMID: 10435626.
      Citations: 57     Fields:    Translation:AnimalsCells
    71. Frankel AE, Lilly M, Kreitman R, Hogge D, Beran M, Freedman MH, Emanuel PD, McLain C, Hall P, Tagge E, Berger M, Eaves C, Frankel AE, Lilly M, Kreitman R, Hogge D, Beran M, Freedman MH, Emanuel PD, McLain C, Hall P, Tagge E, Berger M, Eaves C. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood. 1998 Dec 01; 92(11):4279-86. PMID: 9834234.
      Citations: 6     Fields:    Translation:HumansCells
    72. Matsuguchi T, Lilly MB, Kraft AS, Matsuguchi T, Lilly MB, Kraft AS. Cytoplasmic domains of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor beta chain (hbetac) responsible for human GM-CSF-induced myeloid cell differentiation. J Biol Chem. 1998 Jul 31; 273(31):19411-8. PMID: 9677359.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    73. Lilly M, Kraft A, Lilly M, Kraft A. Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res. 1997 Dec 01; 57(23):5348-55. PMID: 9393759.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    74. Orr RK, Hoehn JL, Col NF, Levin HS, Song J, Scheibel RS, Fletcher JM, Harward H, Lilly M, Goldstein F. Concept formation and problem-solving following closed head injury in children. J Int Neuropsychol Soc. 1997 Nov; 3(6):598-607. PMID: 9448373.
      Citations: 7     Fields:    Translation:Humans
    75. Matsuguchi T, Zhao Y, Lilly MB, Kraft AS, Matsuguchi T, Zhao Y, Lilly MB, Kraft AS. The cytoplasmic domain of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor alpha subunit is essential for both GM-CSF-mediated growth and differentiation. J Biol Chem. 1997 Jul 11; 272(28):17450-9. PMID: 9211889.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    76. Asiedu C, Biggs J, Lilly M, Kraft AS, Asiedu C, Biggs J, Lilly M, Kraft AS. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res. 1995 Sep 01; 55(17):3716-20. PMID: 7641182.
      Citations: 16     Fields:    Translation:HumansCells
    77. Orr RK, Hoehn JL, Col NF, Polotskaya A, Zhao Y, Lilly MB, Kraft AS. Mapping the intracytoplasmic regions of the alpha granulocyte-macrophage colony-stimulating factor receptor necessary for cell growth regulation. J Biol Chem. 1994 May 20; 269(20):14607-13. PMID: 8182067.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    78. Takahashi GW, Andrews DF, Lilly MB, Singer JW, Alderson MR, Takahashi GW, Andrews DF, Lilly MB, Singer JW, Alderson MR. Effect of granulocyte-macrophage colony-stimulating factor and interleukin-3 on interleukin-8 production by human neutrophils and monocytes. Blood. 1993 Jan 15; 81(2):357-64. PMID: 7678512.
      Citations: 24     Fields:    Translation:HumansCells
    79. Andrews DF, Lilly MB, Tompkins CK, Singer JW, Andrews DF, Lilly MB, Tompkins CK, Singer JW. Sodium vanadate, a tyrosine phosphatase inhibitor, affects expression of hematopoietic growth factors and extracellular matrix RNAs in SV40-transformed human marrow stromal cells. Exp Hematol. 1992 May; 20(4):449-53. PMID: 1314736.
      Citations:    Fields:    Translation:Cells
    80. Lilly M, Le T, Holland P, Hendrickson SL, Lilly M, Le T, Holland P, Hendrickson SL. Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene. 1992 Apr; 7(4):727-32. PMID: 1314369.
      Citations: 26     Fields:    Translation:HumansCells
    81. Lilly M, Brown C, Pettit G, Kraft A, Lilly M, Brown C, Pettit G, Kraft A. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia. 1991 Apr; 5(4):283-7. PMID: 2027297.
      Citations: 4     Fields:    Translation:Humans
    82. Lilly M, Tompkins C, Brown C, Pettit G, Kraft A, Lilly M, Tompkins C, Brown C, Pettit G, Kraft A. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Res. 1990 Sep 01; 50(17):5520-5. PMID: 2386956.
      Citations: 4     Fields:    Translation:HumansCells
    83. Kraft AS, William F, Pettit GR, Lilly MB, Kraft AS, William F, Pettit GR, Lilly MB. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res. 1989 Mar 01; 49(5):1287-93. PMID: 2917358.
      Citations: 10     Fields:    Translation:HumansCells
    84. Lilly MB, Kraft AS, Lilly MB, Kraft AS. Leukemia-differentiating activity expressed by the human melanoma cell line LD-1. Leuk Res. 1988; 12(3):217-25. PMID: 3163398.
      Citations: 1     Fields:    Translation:HumansCells
    85. Lilly MB, Devlin PE, Devlin JJ, Rado TA, Lilly MB, Devlin PE, Devlin JJ, Rado TA. Production of granulocyte colony-stimulating factor by a human melanoma cell line. Exp Hematol. 1987 Oct; 15(9):966-71. PMID: 3498641.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    Lilly's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (515)
    Explore
    _
    Co-Authors (56)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _